Recent Advances in the Management of Neovascular Glaucoma

REFERENCES

• Shazly TA, Latina MA. Neovascular glaucoma: Etiology, diagnosis and prognosis. Semin Ophthalmol 2009;24(2):113–121
   PubMed Web of Science ®Google Scholar
• Kubota T, Tawara A, Hata Y, et al. Neovascular tissue in the intertrabecular spaces in eyes with neovascular glaucoma. Br J Ophthalmol 1996;80(8):750–754
   PubMedGoogle Scholar
• Callahan MA. Letter: photocoagulation and rubeosis iridis. Am J Ophthalmol 1974;78(5):873–874
   PubMedGoogle Scholar
• Krill AE, Archer D, Newell FW. Photocoagulation in complications secondary to branch vein occlusion. Arch Ophthalmol 1971;85(1):48–60
   PubMedGoogle Scholar
• Laatikainen L. Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma. Br J Ophthalmol 1977;61(4):278–284
   PubMedGoogle Scholar
• Murphy RP, Egbert PR. Regression of iris neovascularization following panretinal photocoagulation. Arch Ophthalmol 1979;97(4):700–702
   PubMedGoogle Scholar
• Wand M, Dueker DK, Aiello LM, Grant WM. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol 1978;86(3):332–339
   PubMed Web of Science ®Google Scholar
• Michaelson IC. The mode of develoment of the vascular system of the retina with some observations of its significant in certain retinal diseases. Trans Ophthalmol Soc UK 1948;68:137–180
   Google Scholar
• Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007;27(7):816–824
   PubMed Web of Science ®Google Scholar
• Hilton GF. Panretinal cryotherapy for diabetic rubeosis. Arch Ophthalmol 1979;97(4):776
   PubMedGoogle Scholar
• May DR, Bergstrom TJ, Parmet AJ, Schwartz JG. Treatment of neovascular glaucoma with transscleral panretinal cryotherapy. Ophthalmology 1980;87(11): 1106–1111
   PubMedGoogle Scholar
• Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996;149(1):293–305
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335–2342
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669–676
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407(6801):242–248
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331(22):1480–1487
   PubMed Web of Science ®Google Scholar
• Tripathi RC, Borisuth NS, Li J, Tripathi BJ. Growth factors in the aqueous humor and their clinical significance. J Glaucoma 1994;3(3):248–258
   PubMedGoogle Scholar
• Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145(3):574–584
   PubMed Web of Science ®Google Scholar
• Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114(1):66–71
   PubMed Web of Science ®Google Scholar
• Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995;72(6):638–645
   PubMed Web of Science ®Google Scholar
• Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118(4):445–450
   PubMed Web of Science ®Google Scholar
• Sivalingam A, Kenney J, Brown GC, et al. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990;108(6):869–872
   PubMed Web of Science ®Google Scholar
• Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulinlike growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest 1993;92(6):2620–2625
   PubMedGoogle Scholar
• Glaser BM. Extracellular modulating factors and the control of intraocular neovascularization: An overview. Arch Ophthalmol 1988;106(5):603–607
   PubMedGoogle Scholar
• Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113(9):1508, e1501–1525
   Google Scholar
• Friberg TR, Tolentino M, Weber P, et al. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 2010;94(12):1611–1617
   PubMed Web of Science ®Google Scholar
• Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150(3):315–324, e311
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432–1444
   PubMed Web of Science ®Google Scholar
• Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145(2):239–248
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419–1431
   PubMed Web of Science ®Google Scholar
• Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012;13(4):585–591
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36(4):331–335
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26(9):999–1005
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36(4):336–339
   PubMedGoogle Scholar
• Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26(3):279–284
   PubMed Web of Science ®Google Scholar
• Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006;37(2):144–146
   PubMedGoogle Scholar
• Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695, e1691–1615
   Google Scholar
• Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142(6):1054–1056
   PubMedGoogle Scholar
• Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142(1):158–160
   PubMedGoogle Scholar
• Mason JO 3rd, Albert MA Jr, Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006;26(7):839–841
   PubMedGoogle Scholar
• Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142(1):155–158
   PubMed Web of Science ®Google Scholar
• Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009;18(8):632–637
   PubMedGoogle Scholar
• Grover S, Gupta S, Sharma R, et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009;93(2):273–274
   PubMedGoogle Scholar
• Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2010;248(11):1601–1609
   PubMedGoogle Scholar
• Saito Y, Higashide T, Takeda H, et al. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab. Am J Ophthalmol 2010;149(6):964–972, e961
   PubMedGoogle Scholar
• Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115(9):1571–1580, e1571–1573
   PubMed Web of Science ®Google Scholar
• Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007;23(5):487–491
   PubMedGoogle Scholar
• Ehlers JP, Spirn MJ, Lam A, et al. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008;28(5):696–702
   PubMedGoogle Scholar
• Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48(3):314–346
   PubMed Web of Science ®Google Scholar
• The Fluorouracil Filtering Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol 1996;121(4):349–366
   PubMedGoogle Scholar
• Cohen JS, Greff LJ, Novack GD, Wind BE. A placebo-controlled, double-masked evaluation of mitomycin C in combined glaucoma and cataract procedures. Ophthalmology 1996;103(11):1934–1942
   PubMedGoogle Scholar
• Dietze PJ FR, Gross RL. Intraoperative application of 5-fluorouracil during trabeculectomy. Ophthalmic Surg 1992;23(10):662–665
   PubMedGoogle Scholar
• Palanca-Capistrano AM, Hall J, Cantor LB, et al. Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. Ophthalmology 2009;116(2):185–190
   PubMed Web of Science ®Google Scholar
• Zacharia PT, Deppermann SR, Schuman JS. Ocular hypotony after trabeculectomy with mitomycin C. Am J Ophthalmol 1993;116(3):314–326
   PubMedGoogle Scholar
• Greenfield DS, Suner IJ, Miller MP, et al. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996;114(8):943–949
   PubMedGoogle Scholar
• Cornish KS, Ramamurthi S, Saidkasimova S, Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye (Lond) 2009;23(4):979–981
   PubMedGoogle Scholar
• Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 2006;37(2):148–150
   PubMedGoogle Scholar
• Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol 2010;150(3):399–403, e391
   PubMedGoogle Scholar
• Memarzadeh F, Varma R, Lin LT, et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009;50(7):3233–3237
   PubMedGoogle Scholar
• Kapetansky FM, Pappa KS, Krasnow MA. Suconjunctival injection(s) of bevacizumab for failing filtering blebs. Invest Ophthalmol Vis Sci 2007;E-Abstract 837
   Google Scholar
• Purcell JM, Teng CC, Tello C, et al. Effect of needle bleb revision with ranibizumab as a primary intervention in a failing bleb following trabeculectomy. Invest Ophthalmol Vis Sci 2008;E-Abstract 4165
   Google Scholar
• Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy: a pilot study. Ophthalmology 2008;115(12):2141–2145, e2142
   PubMedGoogle Scholar
• How A, Chua JL, Charlton A, et al. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2010;51(2):928–932
   PubMedGoogle Scholar
• Jue A. Angiogenesis: Trabeculectomy and bevacizumab. Semin Ophthalmol 2009;24(2):122–125
   PubMed Web of Science ®Google Scholar
• Yoshida N, Hisatomi T, Ikeda Y, et al. Intravitreal bevacizumab treatment for neovascular glaucoma: Histopathological analysis of trabeculectomy specimens. Graefes Arch Clin Exp Ophthalmol 2011;249(10):1547–1552
   PubMedGoogle Scholar
• Choi JY, Choi J, Kim YD. Subconjunctival bevacizumab as an adjunct to trabeculectomy in eyes with refractory glaucoma: A case series. Korean J Ophthalmol 2010;24(1):47–52
   PubMedGoogle Scholar
• Fakhraie G, Katz LJ, Prasad A, et al. Surgical outcomes of intravitreal bevacizumab and guarded filtration surgery in neovascular glaucoma. J Glaucoma. Mar 2010;19(3):212–218
   PubMedGoogle Scholar
• Gupta V, Jha R, Rao A, et al. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 2009;19(3):435–441
   PubMedGoogle Scholar
• Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther 2008;25(5):438–443
   PubMedGoogle Scholar
• Takihara Y, Inatani M, Kawaji T, et al. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma 2011;20(3):196–201
   PubMedGoogle Scholar
• Bochmann F, Kaufmann C, Becht CN, et al. ISRCTN12125882 – Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma: Study protocol. BMC Ophthalmol 2011;11:1
   PubMed Web of Science ®Google Scholar
• Kim YG, Hong S, Lee CS, et al. Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma. J Glaucoma 2009;18(6):443–447
   PubMedGoogle Scholar
• Sothornwit N. Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thai 2008;91(Suppl 1):S162–165
   Google Scholar
• Altintas AG, Arifoglu HB, Tutar E, et al. Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. Cutan Ocul Toxicol 2012;31(2):124–127
   PubMedGoogle Scholar
• Guerriero E, Yu JY, Kahook MY, et al. Morphologic evaluation of bevacizumab (Avastin) treated corneal stromal fibroblasts. Invest Ophthalmol Vis Sci 2006;E-Abstract 1642
   Google Scholar
• Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26(8):977–982
   PubMedGoogle Scholar
• Yu JY, Kahook MY, Noecker RJ, et al. The effect of avastin on conjunctival fibroblasts. American Glaucoma Society, San Francisco, California. 2007;2 March 2007
   Google Scholar
• O'Neill EC, Qin Q, Van Bergen NJ, et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2010;51(12):6524–6532
   PubMedGoogle Scholar
• Vasuvedan S. Anti-VEGF anti-fibrosis: A comparison of ranibizumab and bevacizumab in vitro. Invest Ophthalmol Vis Sci 2009;E-Abstract 466
   Google Scholar
• Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26(5):512–518
   PubMedGoogle Scholar
• Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006;90(10):1316–1321
   PubMed Web of Science ®Google Scholar
• Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 2010;19(7):437–441
   PubMedGoogle Scholar
• Higashide T, Murotani E, Saito Y, et al. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2012;250(4):603–610
   PubMedGoogle Scholar
• Mete A, Saygili O, Bayram M, Bekir N. Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. J Clin Ultrasound 2010;38(2):66–70
   PubMed Web of Science ®Google Scholar
• Toklu Y, Cakmak HB, Raza S, et al. Short-term effects of intravitreal bevacizumab (Avastin(R)) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration. Acta Ophthalmol 2011;89(1):e41–45
   Google Scholar
• Sacu S, Pemp B, Weigert G, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci 2011;52(6):3046–3050
   PubMed Web of Science ®Google Scholar
• Sagong M, Kim J, Chang W. Intravitreal bevacizumab for the treatment of neovascular glaucoma associated with central retinal artery occlusion. Korean J Ophthalmol 2009;23(3):215–218
   PubMedGoogle Scholar
• von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 2010;88(2):263–266
   PubMed Web of Science ®Google Scholar
• Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95(8):1111–1114
   PubMed Web of Science ®Google Scholar
• Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40(3):293–295
   PubMedGoogle Scholar
• Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250(10):1435–1440
   PubMedGoogle Scholar
• Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina 2011;31(6):1028–1035
   PubMed Web of Science ®Google Scholar
• Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond) 2007;21(12):1541
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56(2):95–113
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897–1908
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular agerelated macular degeneration: two-year results. Ophthalmology 2012;119(7):1388–1398
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92(2):213–216
   PubMed Web of Science ®Google Scholar
• Moradian S, Ahmadieh H, Malihi M, et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008;246(12):1699–1705
   PubMed Web of Science ®Google Scholar